113 related articles for article (PubMed ID: 17099788)
1. [Effectiveness of pegylated liposomal doxorubicin in relapsed ovarian cancer].
Lehoczky O; Pulay T
Magy Onkol; 2006; 50(3):261-4. PubMed ID: 17099788
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
5. Skin-mucous membrane disorder and therapeutic effect of pegylated liposomal doxorubicin in recurrent ovarian cancer.
Yamada Y; Kawaguchi R; Ito F; Iwai K; Niiro E; Shigetomi H; Tanase Y; Kobayashi H
J Obstet Gynaecol Res; 2017 Jul; 43(7):1194-1199. PubMed ID: 28544386
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
Pendlebury A; DeBernardo R; Rose PG
Anticancer Drugs; 2017 Aug; 28(7):815-817. PubMed ID: 28542037
[TBL] [Abstract][Full Text] [Related]
7. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer.
Chambers LM; Pendlebury A; Rose PG; Yao M; DeBernardo R
Gynecol Oncol; 2020 Aug; 158(2):309-315. PubMed ID: 32499072
[TBL] [Abstract][Full Text] [Related]
9. Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.
Collins Y; Lele S
J Natl Med Assoc; 2005 Oct; 97(10):1414-6. PubMed ID: 16353663
[TBL] [Abstract][Full Text] [Related]
10. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
11. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
12. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?
Lorusso D; Naldini A; Testa A; D'Agostino G; Scambia G; Ferrandina G
Oncology; 2004; 67(3-4):243-9. PubMed ID: 15557785
[TBL] [Abstract][Full Text] [Related]
14. Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy.
DiSilvestro PA; Fisher M; Pearl ML; Buhl A; Chalas E; Valea FA
Gynecol Obstet Invest; 2007; 63(1):1-6. PubMed ID: 16809933
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
16. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Marth C
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
[TBL] [Abstract][Full Text] [Related]
18. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
[TBL] [Abstract][Full Text] [Related]
19. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
20. A comparison of overall survival with 40 and 50mg/m
Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
